April 22, 2002

Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk?

Author Affiliations

From the Departments of Medicine (Drs Kushner and Sehgal), Pathology (Dr Kushner), and Epidemiology and Biostatistics (Dr Sehgal) and Center for Biomedical Ethics (Dr Sehgal), Case Western Reserve University; and Division of Nephrology and Center for Health Care Research and Policy, MetroHealth Medical Center (Dr Sehgal), Cleveland, Ohio.


Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002

Arch Intern Med. 2002;162(8):867-869. doi:10.1001/archinte.162.8.867

We evaluate the suggestion that high-sensitivity C-reactive protein testing be used for risk assessment in the primary prevention of cardiovascular disease, using the criteria proposed by the Guide to Clinical Preventive Services developed by the US Preventive Services Task Force. We conclude that at present, none of the 3 major criteria—accuracy, reliability, and likelihood of beneficial intervention— are satisfied.